{"organizations": [], "uuid": "87a9307e6e00fae5fdc83b34c98f710e9f17ba3a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180201.html", "section_title": "Archive News &amp; Video for Thursday, 01 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-roche-holding-ag-ceo-says-no-chang/brief-roche-holding-ag-ceo-says-no-change-in-ma-strategy-idUSFWN1PR08O", "country": "US", "domain_rank": 408, "title": "BRIEF-Roche Holding AG CEO Says No Change In M&A Strategy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-01T14:57:00.000+02:00", "replies_count": 0, "uuid": "87a9307e6e00fae5fdc83b34c98f710e9f17ba3a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-roche-holding-ag-ceo-says-no-chang/brief-roche-holding-ag-ceo-says-no-change-in-ma-strategy-idUSFWN1PR08O", "ord_in_thread": 0, "title": "BRIEF-Roche Holding AG CEO Says No Change In M&A Strategy", "locations": [], "entities": {"persons": [{"name": "john miller", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-roche holding ag", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "roche holding ag", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 1 (Reuters) - Roche Holding Ag:\n* CEO SAYS CONFIDENT NEW DRUGS CAN COMPENSATE FOR OLDER DRUGS LOSING PATENT PROTECTION\n* CEO SAYS ROCHE CAN POTENTIALLY SLIGHTLY GROW BUSINESS DESPITE BIOSIMILARS, INTENDS TO KEEP ‘STRONG MARGINS WHICH WE ENJOY TODAY’\n* CEO SAYS HAS INCREASING CONFIDENCE OVER RECENT PAST THAT ROCHE CAN COMPENSATE FOR BIOSIMILARS\n* CEO SAYS IMPAIRMENT CHARGES ON SEVERAL ITEMS INCLUDING ESBRIET, DUE TO “MODERATE UPTAKE” IN EARLIER LINES OF TREATMENT\n* CEO SAYS VERY CONFIDENT TECENTRIQ TO PLAY LEADING ROLE IN VARIOUS CANCER TYPES\n* CEO SAYS NO CHANGE IN M&A STRATEGY, LOOKING FOR BOLT-ON OPPORTUNITIES TO COMPLEMENT PORTFOLIO Source text for Eikon: Further company coverage: (Reporting by John Miller)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-01T14:57:00.000+02:00", "crawled": "2018-02-02T13:06:39.061+02:00", "highlightTitle": ""}